Sandoz Acquires Astellas' Antifungal Agent Mycamine
The company stated "Through this acquisition of the leading global echinocandin, one of three major antifungal classes, Sandoz significantly reinforces its global hospital offering and leading anti-infectives portfolio.
Stem Cell Transplantation | 29/08/2023 | By Manvi | 298
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy